Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor α (TNF-α) used in adult and pediatric ulcerative colitis (UC) that is initiated in up to 31% of newly diagnosed children with UC by 52 weeks of follow-up (1–5). This evidence concerns the gene TNF and ulcerative colitis.